A recent agreement announced by U.S. President Donald Trump on Thursday with major pharmaceutical companies seeks to enhance access and reduce costs for popular weight-loss medications in the United States. The deal with Eli Lilly and Novo Nordisk will expand Medicare coverage for Zepbound and Wegovy, two GLP-1 receptor agonist drugs. GLP-1 agonists, such as Wegovy and Ozempic, are a category of medications that imitate the GLP-1 hormone to address diabetes and obesity by promoting insulin release, slowing stomach emptying, and curbing appetite.
Limited accessibility in the U.S. has been a challenge due to inconsistent insurance coverage and high prices, which can reach over $500 per month for higher doses. Therefore, the impact of Trump’s announcement on cost reduction is a point of interest. Will Canadians also enjoy these benefits?
The coverage of these medications will be broadened from next year for individuals with severe obesity and those who are overweight or obese with significant health issues. Eligible individuals will have a $50 copay. Additionally, lower prices will be gradually introduced for those without coverage through the TrumpRx program, enabling direct purchase from manufacturers, commencing in January. Officials suggest that drug prices on TrumpRx will start at approximately $350 and decrease to $245 over the next two years.
Although these reductions seem substantial, Canadian pricing is already comparatively lower. Dr. Nisha Gupta, an endocrinologist at McGill University, highlights that GLP-1 drug prices are notably lower in Canada when considering exchange rates.
In Canada, prices for GLP-1 medications, including Ozempic and Wegovy, range from $300 to $500 monthly. Novo Nordisk, the manufacturer of these semaglutide brands, might lose its market exclusivity in Canada in January, potentially leading to the introduction of generic versions. This change could significantly reduce prices, as estimated by Mina Tadrous from the University of Toronto, projecting a drop from $400 to under $100 for the same strength of semaglutide product.
While the availability of generic versions may enhance accessibility, the popularity of GLP-1 drugs in Canada has already contributed to substantial public spending on pharmaceuticals through provincial drug plans. The total spending on prescription drugs for public plans in Canada has increased significantly, with antidiabetic medications like Ozempic playing a significant role in this growth.
Cheaper prices may drive more Canadians to seek prescriptions, potentially including off-label uses not covered by private insurance plans. Some patients currently pay out-of-pocket for GLP-1 drugs, with Wegovy not covered by Canadian provincial governments but possibly covered by private insurers based on specific criteria.
Dr. Gupta emphasizes that if semaglutide becomes generic, it could be more readily accessible to overweight or obese patients. However, prescribing these drugs for unapproved uses will depend on individual physicians’ discretion.
